Celgene, Acceleron begin midstage trial of bone-loss drug

10/16/2008 | American City Business Journals

Celgene and Acceleron Pharma said they have started a Phase II study of ACE-011, a drug candidate designed to treat bone loss in patients with multiple myeloma and other cancers. Acceleron is getting a $5 million milestone payment from Celgene under a collaboration agreement announced in February.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY